Legend Biotech Corp (LEGN) Common Equity (2019 - 2024)
Legend Biotech (LEGN) has disclosed Common Equity for 6 consecutive years, with $1.0 billion as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Common Equity fell 16.85% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2024, down 16.85%, and an annual FY2024 reading of $1.0 billion, down 16.85% over the prior year.
- Common Equity was $1.0 billion for Q4 2024 at Legend Biotech, down from $1.3 billion in the prior quarter.
- Across five years, Common Equity topped out at $1.3 billion in Q4 2023 and bottomed at $597.8 million in Q4 2020.
- Average Common Equity over 5 years is $880.0 million, with a median of $765.9 million recorded in 2021.
- The sharpest move saw Common Equity soared 295.03% in 2020, then dropped 16.85% in 2024.
- Year by year, Common Equity stood at $597.8 million in 2020, then grew by 28.13% to $765.9 million in 2021, then fell by 2.82% to $744.3 million in 2022, then surged by 68.12% to $1.3 billion in 2023, then decreased by 16.85% to $1.0 billion in 2024.
- Business Quant data shows Common Equity for LEGN at $1.0 billion in Q4 2024, $1.3 billion in Q4 2023, and $744.3 million in Q4 2022.